Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 217.41B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 13.40 |
| Forward PE | 11.29 |
| Dividend | 2.91 (3.28%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 1,575 |
| Average Volume | 4,418 |
| Open | 87.60 |
| Previous Close | 88.80 |
| Day's Range | 86.90 - 87.90 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.32 |
| RSI | 65.77 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
SCHD: Tops Dividend Competitors On Value, Yield, And Sustainability
SCHD's top holdings, including Merck and Amgen, combine strong profitability, sustainable payout ratios, and attractive valuations. Read why SCHD ETF is a Buy.
Top 10 High-Yield Dividend Stocks For December 2025
The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks ...
A Look Into Merck & Co Inc's Price Over Earnings
In the current market session, Merck & Co Inc. (NYSE: MRK) stock price is at $104.80, after a 0.03% drop. However, over the past month, the company's stock spiked by 22.97% , and in the past year, by...
Here's Why Merck (MRK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) to Present Promising Alzheimer's Drug Data at Upcoming Conference
Merck (MRK) to Present Promising Alzheimer's Drug Data at Upcoming Conference
MRK a Top 25 Dividend Giant With $41.48B Held By ETFs
Merck & Co Inc (Symbol: MRK) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a staggering $41.48B worth of stock held by ETFs, and above-average ''DividendRank'' statistics includin...
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2...
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025.
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders
Merck is a high-yield drug stock with a well-supported dividend payment. Enbridge is a boring energy stock with a hefty yield.
3 Non-AI Stocks to Buy: MRK, UPS, CVX
There are plenty of potential winners outside the world of AI.
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?
One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that could help the company overcome its challenges.
Merck: Excellence Across The Board
Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance a...
IHE: Pharma Powerhouse ETF Despite High Fees And Valuation
iShares U.S. Pharmaceuticals ETF offers growth and dividends from top holdings like LLY, JNJ, MRK with strong earnings and sector focus. See why IHE ETF is a buy.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck's Janumet to See 85% Price Reduction Under Medicare Negotiations
Merck's Janumet to See 85% Price Reduction Under Medicare Negotiations
Why Is Merck Stock Surging?
Merck (MRK)'s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings excee...
Merck to Participate in the Citi 2025 Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Citi 2025 Global Healthcare Conference.
Merck to Participate in the Citi 2025 Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of g...
Merck Reaches Analyst Target Price
In recent trading, shares of Merck & Co Inc (Symbol: MRK) have crossed above the average analyst 12-month target price of $103.30, changing hands for $105.66/share. When a stock reaches the target an ...
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference.
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of g...
Dow Movers: NVDA, MRK
In early trading on Tuesday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.8%. Year to date, Merck registers a 3.7% gain. And the w...
Kelun phase 3 ADC trial with Merck's Keytruda for NSCLC meets primary endpoint
Kelun Biotech's sac-TMT plus Merck's Keytruda shows significant progress in late-stage lung cancer trial. Read more here.
Dow Movers: PG, MRK
In early trading on Monday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 3.1%. Year to date, Merck registers a 1.3% gain. And the wo...
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.